Tag Archives: investing

Hot Investor Mandate: Early-Stage Focused VC Invests in Pre-Seed and Seed Stage Deeptech Companies, Including Synbio and Data Driven Technologies

12 Aug

This venture capital firm invests in pre-seed to seed stage opportunities with initial check sizes ranging from $500k to $1M and maintains reserves for follow-on capital. While the firm prefers to lead deals, it is open to syndication. Investment geography spans both Europe and the United States. 
 

The investment team has a deep technical background in software, artificial intelligence, and algorithms. Within life sciences and healthcare, the firm is focused on techbio, synthetic biology, computational biology, chemistry & materials. 

The firm is also open to hardware (e.g., diagnostics or medical devices) that enable novel data modalities, digital health, and therapeutic platforms. 

However, the firm does not invest in traditional therapeutic assets and is indication-agnostic. Opportunities can be considered as early as the pre-prototype stage, provided there is a roadmap toward intellectual property or patent protection. 

There are no strict team or company prerequisites, though the firm has a preference for technical founders with strong scientific grounding. The firm may take a board or observer seat depending on the opportunity. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Fund With US and China Operations Seeks to Invest in Seed to Growth Stage Medical Devices, Diagnostics, and Digital Health

5 Aug

This venture capital fund was established by a group of high-net-worth individuals in China and maintains operations in the US and China. The firm is actively seeking global investment opportunities, with a primary focus on China and the United States. Opportunities based in Canada, Germany, and Switzerland may also be considered. 

The firm invests from seed and early stages through growth, with flexibility on check size for early-stage deals. For growth-stage companies, the firm typically invests $1-5M in equity in businesses with valuations up to $18-20M. Investments at earlier stages may take the form of equity or convertible notes. Thanks to an evergreen fund structure, the firm is able to take a long-term investment approach. It usually syndicates investments and seeks to partner with local co-investors, particularly for overseas deals. 

 
The firm targets high-growth sectors, including medical devices, diagnostics (e.g., portable imaging, high-intensity ultrasound, point-of-care, molecular diagnostics), digital health (particularly connected devices, telemedicine, and patient-physician platforms relevant to the Chinese market), and consumer products, especially OTC products, nutritional and dietary supplements with proven efficacy and existing market presence. 
 

The firm is indication-agnostic and prioritizes serial entrepreneurs and complete, well-rounded founding teams. It relies on local co-investors to play supervisory roles in international ventures. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: China-Based Investment Firm Backs Companies and Funds, with Strong Interest in Therapeutics and Medtech Companies With Local Market Fit

5 Aug

An investment firm headquartered in China invests in both fund-of-funds and direct equity opportunities. Life sciences and healthcare represent one of its primary focus areas, though the firm maintains a multi-sector approach. Its investment sweet spot begins at the pre-A stage and extends through to pre-IPO. While the firm primarily targets opportunities within China, it is open to global companies, particularly those seeking a soft landing in China or with a strong China angle. The firm is flexible on deal structure and is open to both leading investments and co-investments. 

Within the healthcare and life sciences sector, the firm is especially interested in biotech therapeutics and medtech. On the therapeutics side, it is open to a range of modalities (excluding mRNA) and indications, with particular interest in areas such as central nervous system (CNS) disorders and oncology. On the medical device side, the firm prioritizes innovative technologies, including invasive solutions, imaging platforms, and brain-computer interfaces. It does not invest in non-innovative categories such as consumables. 

The firm does not maintain strict requirements regarding the background of founding teams, though it has a strong preference for companies that are interested in expanding into Shanghai or the broader Chinese market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Early-Stage VC Focused on Deeptech Innovation, Investing in Platform and Enabling Technologies from Pre-Seed to Series A

5 Aug

An early-stage venture capital firm focuses on deeptech innovation, with strategic emphasis on the Cleantech and Biotech sectors. The firm acknowledges the critical role that advanced materials play in promoting both planetary and human health. 

The firm typically invests from Pre-Seed through Series A, with average initial allocations around USD $500k and reserves for follow-on participation. Geographically, the firm targets North America and Asia, and is also open to public-ready companies or those preparing to go public. 

Within biotech, the firm seeks novel therapeutics and global health-enhancing medical breakthroughs. While broadly sector-agnostic, the firm prioritizes companies with a technology backbone. Preferred areas include: platform technologies, enabling tools for drug discovery & development, and synthetic biology 

The firm is indication-agnostic, though generally less interested in infectious diseases. 

There are no strict team or company prerequisites, though the firm prefers to have an investor presence on the board. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Canada-Based VC Invests in AI-Driven Technologies Including Medical Devices, Diagnostics, and Digital Health Across the Globe

5 Aug

A venture capital corporation is based in Canada with the government serving as a limited partner participates in Angel through Series A rounds, typically allocating CAD $100K to $200K for Angel rounds and CAD $500K to $1M for Pre-A and Series A rounds. It is open to co-investments and occasionally acts as a limited partner in other investment funds. The firm seeks innovative projects that align with the interests of its affiliated operating company, which specializes in immunology-based diagnostics. 

In addition to direct investments, the firm in-licenses intellectual property from universities and engages in joint ventures with other partners. With its own internal management and engineering team, the firm plays an active role in helping startups enter the market and commercialize their products. The firm is open to working with companies globally. 

Its core areas of interest include AI-driven digital health, medical devices, and diagnostics – particularly those involving antigen and antibody pairs. The firm favors companies that are nearing commercialization and can be integrated into its existing AI platform. A board seat is typically preferred in investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

China’s Biotech Boom: Innovation, Influence, and Rising Tensions 

5 Aug

By Sougato Das, President and COO, LSN

Sougato-Das

As 2025 progresses, China’s biotech and pharmaceutical sectors are not just growing—they’re reshaping the global industry landscape. With skyrocketing innovation, bold regulatory reform, and a deepening rivalry with the U.S., Chinese biotech firms are asserting their global presence at unprecedented speed. The GSK / Hengrui Pharma deal, involving a major collaboration potentially worth up to $12.5 billion, is the latest example. The deal focuses on developing up to a dozen drug candidates, primarily in respiratory diseases, immunology, infection, and oncology. GSK will pay Hengrui an upfront fee of $500 million, with the potential for significant milestone payments and royalties if the collaboration is successful. China will continue to play a major role in the worldwide biopharma ecosystem as…

China Emerges as a Global Drug Development Powerhouse

  • Record Licensing Activity: China-to-West drug licensing hit a record $41.5 billion in 2024, a staggering 66% jump from the previous year. Nearly 30% of global innovative drug assets now trace their origin to China.
  • Biotech Licensing Leadership: In 2024, 42% of all global biotech licensing deals over $50 million involved Chinese firms—up from 22% in 2023.

Drug Discovery Is Going East

  • Rapid Shift in Molecule Sourcing: One in three externally sourced molecules by global biopharma firms now comes from China—a dramatic rise from virtually none in 2019. Chinese biotech firms are lauded for their speed, efficiency, and low-cost synthesis of new compounds, positioning them as preferred partners for drug discovery.

Clinical Trials and Regulatory Momentum increases in China

  • China’s Clinical Surge: In 2023, nearly 28% of global clinical trial sponsorships originated from China—up from just 4% a decade ago. Registrations alone rose by 26% last year.
  • Faster to Market: Thanks to reforms by China’s National Medical Products Administration (NMPA), investigational new drugs can now be approved for human testing in just 60 working days.
  • FDA Recognition: Chinese trials are increasingly qualifying for FDA priority pathways, challenging the traditional dominance of U.S.-based clinical development.

China is at the Cutting Edge of Gene Editing

  • CRISPR Leadership: Chinese startups like YolTech (in vivo CRISPR therapy) and Huidagene (brain-targeted CRISPR trials) are leading in next-gen gene editing.
  • Global Recognition: According to Goldman Sachs, China is at the forefront of CRISPR and CAR-T research.

Tensions and Regulatory Hurdles deepen with the US

  • Geopolitical Pressure: Proposed U.S. legislation—the BIOSECURE Act—would prohibit drugmakers with federal contracts from using Chinese firms like WuXi AppTec and WuXi Biologics after 2032. This could disrupt global supply chains and complicate R&D strategies for U.S. companies.
  • Scientific Chilling Effect: Fears of increased scrutiny are causing some Chinese and Chinese-American researchers to avoid applying for NIH grants, impacting U.S.-China scientific collaboration.
  • Investment Headwinds: Despite innovation, venture capital investment in Chinese biotech has declined due to geopolitical uncertainty.

Cross-Border Deals Multiply

  • Western Biopharma Engagement: U.S. and European firms are actively pursuing licensing and partnership deals with Chinese biotechs—particularly in ADC and bispecific antibody platforms, expanding beyond oncology.
  • Investor Sentiment Splits: Some U.S. investors advocate for protectionist strategies, while others see China’s rise as an opportunity for strategic alignment and access to novel therapies.

What Does All This Means for the Industry>

China is no longer simply a “fast follower” in biotech. It’s now an originator of breakthrough science, shaping the future of global drug development, even as geopolitical tensions threaten to redraw the map of international collaboration.

As global biopharma leaders and investors reassess their strategies, one thing is clear: ignoring China’s biotech ascent is no longer an option.

Tags: , , , , , , , , , , ,

JPM 2026: Partnering, Event/Reception Space Available at RESI JPM

29 Jul

Host your event. Launch your brand. Meet your partners.

By Sougato Das, President and COO, LSN

Sougato-Das

Life Science Nation (LSN) has secured a 20,000 square foot (1900 square meters) space at the Marriott Marquis in Union Square in the heart of JPM Week 2026. This premium venue will serve as the headquarters for the Redefining Every Stage of Investment (RESI) conference on Monday and Tuesday, January 12 and 13—but we’re opening the doors Sunday, January 11 for groups looking to host their own event in the center of the action.

We’re inviting economic development agencies, global trade organizations, venture groups, and industry associations to partner with LSN or book standalone time in this flagship location.

The Space

  • 20,000 square feet of meeting and activation space
  • 4 fully equipped conference rooms (2400 square feet/220 square meters), good for theater-style seating for presentations or a small networking event
  • 90+ RESI-style partnering tables
  • Full-service meeting logistics support available

This space is ideal for:

  • Networking receptions, investor briefings, and pitch showcases
  • Country or region-specific innovation days
  • Workshops, roundtables, or startup presentations
  • Private investor or industry partner meetings

Flexible Integration Options

  • January 11 (Sunday): Available for standalone programs, private events, or pre-RESI activities
  • January 12 and 13 (Monday and Tuesday): Integrate into the RESI JPM program, gain access to hundreds of global investors, and use the space to host partner meetings or specialized tracks within the RESI ecosystem

LSN is already in discussion with a range of organizations, including tech hubs, economic development agencies, service providers, and nonprofit patient groups who are seeking affordable options for hosting events and partnering at JPM.

Why Co-Locate with LSN During JPM?

  • Prime Union Square location just steps from the major hotel hubs and investor meetings
  • Built-in foot traffic and visibility from RESI attendees, investors, and partners
  • Flexible use of infrastructure and logistics support from the LSN team
  • Branding and signage opportunities throughout the venue
  • Streamlined meeting scheduling and visibility if integrated into the RESI partnering platform

Make It Yours

Whether you’re looking to host a private country reception, a thematic track inside RESI, or a custom event that aligns with your mission, the space is move-in ready and centrally located. We can help with meeting set-up, agenda development, signage, staffing, registration flow, and more.

Interested in booking or learning more?
Contact salescore@lifesciencenation.com to discuss options, availability, and pricing.

Let’s create a high-impact presence for your organization at the most important week in global life sciences.

Tags: , , , , , , , , , ,

← Older Entries
Newer Entries →